Tumor Ablation Market Report 2025

This Tumor Ablation market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The tumor ablation market size has grown rapidly in recent years. It will grow from $1.45 billion in 2024 to $1.62 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to the development of more precise and efficient ablation techniques, rising healthcare expenditure across emerging economies, the demographic shift towards older populations, the increasing burden of cancer, and the rising prevalence of cancer globally.

The tumor ablation market size is expected to see rapid growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing cancer incidence, growing minimally invasive procedures, expanding applications, increasing healthcare cost-effectiveness, and growing awareness and education. Major trends in the forecast period include technological advancements, Continued development of advanced ablation technologies, integration of artificial intelligence, focus on outpatient settings, and patient-centric approaches.

The tumor ablation market is poised for growth due to the increasing adoption of minimally invasive procedures. Minimally invasive procedures involve medical or surgical interventions that require small incisions or no incisions at all, driven by their benefits such as reduced recovery times, lower complication risks, and less post-operative pain compared to traditional surgeries. Tumor ablation techniques, including radiofrequency, microwave, or cryoablation, are employed in these procedures to destroy cancerous tissues while minimizing damage to surrounding healthy tissue, further contributing to quicker recovery times. For example, Intuitive Surgical Inc. reported a 12% increase in placements of da Vinci surgical systems, which facilitate minimally invasive approaches, in the fourth quarter of 2023 compared to 2022, underscoring the momentum behind minimally invasive procedures and, consequently, the tumor ablation market's growth.

Leading companies in the tumor ablation market are focusing on innovation to enhance treatment effectiveness and broaden the scope of treatable tumors. One area of innovation is the development of specialized products such as bone tumor ablation systems. These systems are designed specifically for minimally invasive procedures to treat bone tumors. Recently, Medtronic plc received FDA 510(k) clearance for its OsteoCool 2 bone tumor ablation system in March 2024. This upgraded system is tailored for treating painful bone metastases and benign bone tumors such as osteoid osteoma. It allows for the simultaneous use of four internally cooled probes, offering greater flexibility in treatment. The system delivers enhanced power, significantly exceeding that of comparable systems such as the Stryker OptaBlateTM bone tumor ablation system.

In December 2022, Boston Scientific Corporation, a US-based biomedical manufacturing company, acquired Acotec Scientific Holdings Ltd. for $523 million. Through this acquisition, Boston Scientific aims to enhance its presence in China and globally commercialize the product portfolio of Acotec Scientific. Acotec Scientific Holdings Ltd., a China-based medical technology company, specializes in radiofrequency ablation technologies, drug-coated balloons, and thrombus aspiration catheters.

Major companies operating in the tumor ablation market are Abbott Laboratories, Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Varian Medical Systems Inc., Merit Medical Systems Inc., Bioventus LLC, Accuray Incorporated, AtriCure Inc., AngioDynamics Inc., EDAP TMS S.A., NeuWave Medical Inc., Mirabilis Medical Inc., STARMed Co. Ltd., Profound Medical Corp., RF Medical Co. Ltd., IceCure Medical Ltd., MedWaves Inc., Chongqing Haifu Medical Technology Co. Ltd.

North America was the largest region in the tumor ablation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor ablation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor ablation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tumor ablation is a minimally invasive medical procedure designed to eliminate cancerous tissues by applying extreme heat, cold, or chemical agents directly to the tumor, causing cell death. This approach is commonly used for treating small tumors or those located in challenging anatomical locations.

The primary types of tumor ablation include thermal ablation and chemical ablation. Thermal ablation involves using extreme heat to destroy abnormal or diseased tissue, and it is employed across various treatments such as percutaneous, laparoscopic, and surgical procedures for conditions such as kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, among others. End users of these techniques include hospitals, oncology centers, and other healthcare facilities.

The tumor ablation market research report is one of a series of new reports that provides tumor ablation market statistics, including the tumor ablation industry's global market size, regional shares, competitors with a tumor ablation market share, detailed tumor ablation market segments, market trends and opportunities, and any further data you may need to thrive in the tumor ablation industry. This tumor ablation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tumor ablation market includes revenues earned by entities by providing services such as consultation, diagnosis, chemical ablation, and post-procedure care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.